Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs
Open Access
- 2 October 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1243457
Abstract
Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that can infect all body tissues and organs. In particular, the lungs are the most commonly involved organ, with NTM pulmonary diseases causing serious health issues in patients with underlying lung disease. Moreover, NTM infections have been steadily increasing worldwide in recent years. NTM are also naturally resistant to many antibiotics, specifically anti-tuberculosis (anti-TB) drugs. The lack of drugs targeting NTM infections and the increasing drug resistance of NTM have further made treating these mycobacterial diseases extremely difficult. The currently recommended NTM treatments rely on the extended indications of existing drugs, which underlines the difficulties of new antibiotic discovery against NTM. Another challenge is determining which drug combinations are most effective against NTM infection. To a certain extent, anti-NTM drug development depends on using already available antibiotics and compounds. Here, we aimed to review new antibiotics or compounds with good antibacterial activity against NTM, focusing on their mechanisms of action,in vitroandin vivoantibacterial activities.Keywords
This publication has 139 references indexed in Scilit:
- Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- Sternal Wound Infection Caused by Mycobacterium chelonaeJournal of Cardiac Surgery, 2013
- Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure InfectionsJAMA, 2013
- Comparative Drug Resistance of Mycobacterium abscessus and M. chelonae Isolates from Patients with and without Cystic Fibrosis in the United KingdomJournal of Clinical Microbiology, 2013
- Delamanid for Multidrug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2012
- An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2007
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLOS Medicine, 2006
- Disseminated Nontuberculous Mycobacterial Infections in Sickle Cell Anemia PatientsJournal of Pediatric Hematology/Oncology, 2006
- Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous MycobacteriaAntimicrobial Agents and Chemotherapy, 2002
- LinezolidDrugs, 2000